https://pmc.ncbi.nlm.nih.gov/articles/PMC3391993/
The role of BRAF V600 mutation in melanoma - PMC
BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 %...
the rolebraf v600mutationmelanomapmc
https://www.hmpgloballearningnetwork.com/site/onc/news/hsk42360-shows-clinical-promise-braf-v600-mutant-glioma
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas....
braf v600showsclinicalpromisemutant
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01682083&r=1
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive...
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).